A carregar...
Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia
The introduction of the tyrosine kinase inhibitor (TKI) imatinib has revolutionised the outlook of chronic myeloid leukemia (CML); however, a significant proportion of patients develop resistance through several mechanisms, of which acquisition of ABL1 kinase domain mutations is prevalent. In chroni...
Na minha lista:
| Publicado no: | Case Rep Hematol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5742436/ https://ncbi.nlm.nih.gov/pubmed/29375916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/3548936 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|